The Korea Times close
National
  • Politics
  • Diplomacy
  • Defense
  • Labor & Environment
  • Law & Crime
  • Health & Welfare
  • Embassy
  • Seoul & Provinces
  • Education
  • Foreign Communities
  • Obituaries
Biz & Tech
  • Auto
  • IT
  • Game
  • Manufacturing
  • Retail & Food
  • Energy
  • Construction
  • Airlines
Finance
  • Policies
  • Economy
  • Markets
  • Banks
  • Non-banks
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to the Editor
Lifestyle
  • Arts
  • Books
  • Travel & Cuisine
  • Trend
  • Fashion
  • Around Town
  • Fortune Telling
Entertainment
  • K-pop
  • K-dramas & Shows
  • Movies
  • Music
  • Performances
  • Asia Model Festival
Sports
  • Football
  • Golf
  • Baseball
  • Other Sports
World
  • Asia Pacific
  • Americas
  • Europe & Africa
  • SCMP
Video
  • On the Spot
  • Feature
  • News
Photos
  • Photo News
  • Darkroom
Community
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
National
  • Politics
  • Diplomacy
  • Defense
  • Labor & Environment
  • Law & Crime
  • Health & Welfare
  • Embassy
  • Seoul & Provinces
  • Education
  • Foreign Communities
  • Obituaries
Tue, March 2, 2021 | 14:45
Celltrion to launch COVID-19 treatment soon
Posted : 2020-12-29 16:43
Updated : 2020-12-30 09:15
Mail
Print Preview
Font Size Up
Font Size Down
Celltrion's COVID-19 treatment CT-P59 / Courtesy of Celltrion
Celltrion's COVID-19 treatment CT-P59 / Courtesy of Celltrion

By Nam Hyun-woo

Celltrion is expected to launch its COVID-19 treatment as early as next month, raising hopes that it will be able to combat the new coronavirus strain which is causing fear due to its high transmissibility.

The company said it has applied for conditional approval for its CT-P59 treatment from the Ministry of Food and Drug Safety. Conditional approval is given to a new drug that has finished Phase 2 clinical trials, if there is no other treatment for the disease. The drug developer is required to continue with and finish full clinical trials at the same time.

Hours after receiving Celltrion's application, the ministry said it has begun its review.

Earlier this week, the ministry said it will shorten the review period for drugs to treat COVID-19 from 180 days to 40 days. Given this, the treatment is anticipated to become available in late January.

The Phase 2 trials were conducted on 327 patients in Korea, Romania, Spain and the U.S., and final treatment injections took place Nov. 25. Celltrion said it decided to apply for domestic approval immediately after the trials, because "the company believes it has secured enough evidence and data to file for approval."

Since the trials were designed in coordination with the ministry, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency, the company is expecting the emergency approval processes to proceed smoothly in those regions. The company plans to apply for emergency use authorization in the U.S. and Europe next month, and will launch contiguous Phase 3 clinical trials in 10 countries soon.

If Celltrion's treatment gets domestic approval, it will be the world's third company to develop a COVID-19 treatment from scratch, following Eli Lilly and Regeneron.

In a conference held Monday, Celltrion Vice Chairman Kee Woo-sung said CT-P59 is designed for the early treatment of mild COVID-19 cases, and the company has confirmed that the drug is effective against all variants of the coronavirus.

The fear over new COVID-19 strains is growing in Korea. The Central Disease Control Headquarters has confirmed that a mutated coronavirus strain that's been spreading in the U.K. infected three Koreans who entered Korea, Dec. 23.

Overseas news outlets are reporting that the variant could be up to 70 percent more infectious than others already in circulation. Though the government said Tuesday there is "slim chance of the U.K. variant circulating in the country," public fear is growing as the U.K. and other variants are spreading rapidly across the globe.

Following Celltrion's announcement, the company's share price rose, closing at 360,500 won, Tuesday, up 10.8 percent from the previous session.

As conditional approval is expected, Celltrion sent text messages to its employees and executives Sunday asking for them to stop trading any shares they held in the company and its two listed affiliates.

"Due to our development of a COVID-19 treatment, public attention is high on employees' and executives' trading of company shares," the message read. "Until the treatment gets approval, employees and their family members are asked not to trade listed Celltrion Group shares."

The message, however, came after eight executives and their family members sold more than 30,000 Celltrion shares. Of them, Celltrion Holdings Vice Chairman Yoo Heon-young sold 10,000 shares, worth about 3.6 billion won, followed by Executive Director Baek Kyung-min who sold 7,078 shares worth 2.5 billion won.


Emailnamhw@koreatimes.co.kr Article ListMore articles by this reporter









 
 
  • South Korea's next generation jet KF-X set to roll out, boost local defense industry
  • Growing pains of Korea's leading internet firms
  • Moon's continued two-track approach unlikely to help improve ties with Japan
  • Bloody Sunday in Myanmar
  • Woman fined for breaking quarantine to visit dying father
  • New moms in their 20s becoming increasingly rare
  • Portion of male births of newborns hits record low
  • McKinsey set to entice Oliver Wyman Korea's clients
  • Myanmarese workers in Korea stage democracy rally [VIDEO]
  • Loan interest rates rise sharply
  • Stray Kids' Hyunjin admits to bullying, takes hiatus from performing Stray Kids' Hyunjin admits to bullying, takes hiatus from performing
  • 'Minari' wins best foreign-language film at 2021 Golden Globes 'Minari' wins best foreign-language film at 2021 Golden Globes
  • K-pop girl group members accused of ostracizing bandmate K-pop girl group members accused of ostracizing bandmate
  • Lady Gaga's dogs recovered safely after theft, shooting Lady Gaga's dogs recovered safely after theft, shooting
  • BTS wins Song of the Year, Best Pop Song Award at Korean Music Awards BTS wins Song of the Year, Best Pop Song Award at Korean Music Awards
DARKROOM
  • Bloody Sunday in Myanmar

    Bloody Sunday in Myanmar

  • Earth is suffering

    Earth is suffering

  • NASA's Perseverance rover is landing on Mars

    NASA's Perseverance rover is landing on Mars

  • Fun in the snow, sledding for everyone

    Fun in the snow, sledding for everyone

  • Our children deserve better: Part 3

    Our children deserve better: Part 3

  • About Korea Times
  • CEO Message
  • Times History
  • Content Sales
  • Media Kit
  • Contact Us
  • Location
  • Privacy Statement
  • Terms of Service
  • Mobile Service
  • RSS Service
  • 고충처리인
  • hankookilbo
  • Dongwha Group
  • Code of Ethics
Copyright